Coherus Oncology, Inc.

Good day and thank you for standing by. Welcome to the Q1 2026 Coheris Oncology Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star 1, 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1, 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carrie Graham. Please go ahead.

Thank you, Heidi. Good afternoon, and welcome to Coherent Oncology's first quarter 2026 earnings conference call. Joining me today to discuss our results are Denny Lancer, Chief Executive Officer of Coherent, Dr. Rosh Dias, Chief Medical Officer, Dr. Theresa Lavallee, Chief Scientific and Development Officer, Samira Ghori-Gokhar, Chief Commercial Officer, and Brian McMichael, Chief Financial Officer. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding COHER's current expectations about future events. Actual results may vary significantly, and we undertake no duty to update or revise any forward-looking statements. Please see the press release that we issued today and our quarterly report on form 10Q for more information on risks and uncertainties. And now I'll turn the call over to Denny.

Well, thank you, Carrie. And thank you all for joining us this afternoon on our Q1 2026 quarterly call. Let me first give you a quick flyby of the company's strategy to make sure we level set everyone, including our new investors. That strategy starts with Bactorsi, our next generation differentiated PD-1 inhibitor, which is both a revenue generator in the context of nasal pharyngeal cancer, and a revenue multiplier in the context of its combination with the novel molecules in our pipeline, such as Casdoso ketone, which we are exploring in liver cancer, and Tegmo ketone, which we are exploring across a number of cancer indications, including gastrointestinal, head and neck, and most recently, prostate cancer. We are executing a well-integrated financial, commercial, and development strategy that maximizes Lactorsi's potential across both these dimensions while moving the pipeline forward efficiently. NPC is large enough to cover the core cash burn at a projected $175 million a year at peak share, which does not include clinical trial costs, something which we view separately. Proprietary combinations of Lactorsi with the pipeline ASLIT translates to a two-for-one win. Label expansion for Lactorsi included upon any approval. This will, of course, also translate to commercial synergies. This is how we can target $33 billion in market opportunity with our current efforts. The third leg of the strategic triad is a Treg depletion with Tegmo-Ketog across cancers and across non-proprietary combinations which we view as a foundational Treg depletion platform and not merely another checkpoint adjunct. We further wish to explore Treg depletion as a potential new scaffold across cancer therapies. Tregs broadly mediate immune response and cancer hijacks immune mediation to grow and proliferate. Many cancer therapies either result in or are limited by Tregs gonorrhea. Our strategic objective then is to broadly deploy TAGMO-T across cancers and non-proprietary therapies. Last quarter, we concluded the first such arrangement with J&J in prostate with PASRI, a T-cell engager. We are currently exploring other partnering opportunities, which include not just T-cell engagers, but ADCs, radiotherapy, and various biospecifics. Now, as we have been saying for some time across all of our presentations, CCRA-based Treg depletion could be challenging for a lot of reasons. You need to have the right molecule and the right target. The right molecule translates to a number of things across selectivity, affinity, pharmacology, and all the rest. And the right target translates to immune context and the nuances of the biology. Recently, it's become clear that the therapeutic promise of Treg depletion notwithstanding, some market participants are pausing or stopping the programs. while others are accelerating and expanding the programs. It's essential for all of us to understand the nuances playing out. Accordingly, I've asked my Chief Scientific Officer, Teresa Lavalle, to spend a few minutes with you today and provide a lens through which to view the field's evolution. I hope you find it useful. Also today, Raj Dias, our Chief Medical Officer, will update you on the trials, enrollment, and the timing results. Samira Golodgako will review the Q1 revenues as well as provide an update on our commercial execution. We continue to project that we will hit some $15 million per quarter sometime this year in 2026 and $30 to $35 million per quarter sometime in 2027 and a market share peak of about $44 million per quarter sometime in 2028, which translates to about $175 million a year. After Samir, Brian McMichael will review for you our financials. And with that, now let me turn the call over to Raj. Dr. Dias?